Breathe Technologies: Penetrating The Ventilator Market

Breathe Technologies is bringing a bit of disruption to the staid ventilator market: NIOV, a portable ventilator, can help patients breathe easier both inside and outside the hospital. But perhaps because innovation in this field isn’t common, the company is meeting resistance from some payors, most notably the Centers for Medicare and Medicaid Services, which doesn’t see the device as a ventilator but rather another form of oxygen therapy.

Here’s a simple fact about health care: no drug or device will improve a person’s health if he can’t draw a simple breath. Without the ability to draw complete tissue-enriching oxygen to the entire body, an otherwise healthy person is resigned to a life of headaches, fatigue, pain, and loss of cognition skills. Without relief, this shortness of breath – or dyspnea – will continuously pull a person down into a prison of immobility and, eventually, death. A healthy person needs only to spend a short time taking all of his air through a drinking straw to appreciate the awful sensation.

At some point, the downward spiral will land a person in a hospital bed or another clinical setting where a...

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By 

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.